The second Geneva Consensus: Recommendations for novel live TB vaccines

Vaccine

Volumn 28, Issue 11, 2010, Pages 2259-2270

  Walker, K B ^a   Brennan, M J ^b   Ho, M M ^a   Eskola, J ^c   Thiry, G ^d   Sadoff, J ^d   Dobbelaer, R ^e   Grode, L ^f   Liu, M A ^g,h   Fruth, U ^h   Lambert, P H ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^b Sequella Global TB Foundation   (United States)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^d Waasmunsterbaan 26 ^*  (United States)

^e Vakzine Projekt Management GmbH   (Belgium)

^f ProTherImmune   (United States)

^g KAROLINSKA INSTITUTE   (Sweden)

^h WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Clinical development; Clinical trial; Live vaccines; Preclinical development; Tuberculosis

Indexed keywords

BCG VACCINE; LIVE VACCINE; MYCOBACTERIUM TUBERCULOSIS MC2 6020; MYCOBACTERIUM TUBERCULOSIS MC2 6030; MYCOBACTERIUM TUBERCULOSIS PHOP; RECOMBINANT BACILLUS CALMETTE GUERIN; RECOMBINANT BACILLUS CALMETTE GUERIN UREC:HLY; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; BCG VACCINATION; CLINICAL TRIAL; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; GOOD MANUFACTURING PRACTICE; HUMAN; IMMUNE RESPONSE; MASS IMMUNIZATION; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TRANSGENIC ORGANISM; TUBERCULOSIS;

BIOMEDICAL RESEARCH; HUMANS; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINES, ATTENUATED;

EID: 77349109263     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.12.083     Document Type: Conference Paper

References (84)

1. Global tuberculosis control. Epidemiology, strategy, financing. WHO Report 2009 (2009), World Health Organisation
2. Aeras Tuberculosis Vaccine Candidates. http://www aeras org/our-approach/vaccine-development php?portfolio; 2009.
3. Barker L.F., Brennan M.J., Rosenstein P.K., and Sadoff J.C. Tuberculosis vaccine research: the impact of immunology. Curr Opin Immunol 21 Jun (3) (2009) 331-338
4. McShane H. Vaccine strategies against tuberculosis. Swiss Med Wkly 139 Mar (11-12) (2009) 156-160
5. Smith R. Eradication of tuberculosis by 2050 impossible without new vaccine. BMJ 338 (2009) b1291
6. TBVAC.org - Candidates. http://www tb-vac org/works htm; 2009.
7. Aagaard C., Dietrich J., Doherty M., and Andersen P. TB vaccines: current status and future perspectives. Immunol Cell Biol 87 May (4) (2009) 279-286
8. Kamath A.T., Fruth U., Brennan M.J., Dobbelaer R., Hubrechts P., Ho M.M., et al. New live mycobacterial vaccines: the Geneva consensus on essential steps towards clinical development. Vaccine 23 May (29) (2005) 3753-3761
9. Behr M.A., Wilson M.A., Gill W.P., Salamon H., Schoolnik G.K., Rane S., et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 284 May (5419) (1999) 1520-1523
10. Behr M.A., and Small P.M. A historical and molecular phylogeny of BCG strains. Vaccine 17 Feb (7-8) (1999) 915-922
11. Brosch R., Gordon S.V., Garnier T., Eiglmeier K., Frigui W., Valenti P., et al. Genome plasticity of BCG and impact on vaccine efficacy. Proc Natl Acad Sci USA 104 Mar (13) (2007) 5596-5601
12. Brosch R., Gordon S.V., Buchrieser C., Pym A.S., Garnier T., and Cole S.T. Comparative genomics uncovers large tandem chromosomal duplications in Mycobacterium bovis BCG Pasteur. Yeast 17 Jun (2) (2000) 111-123
13. Brosch R., Gordon S.V., Marmiesse M., Brodin P., Buchrieser C., Eiglmeier K., et al. A new evolutionary scenario for the Mycobacterium tuberculosis complex. Proc Natl Acad Sci USA 99 Mar (6) (2002) 3684-3689
14. Asensio J.A., Arbues A., Perez E., Gicquel B., and Martin C. Live tuberculosis vaccines based on phoP mutants: a step towards clinical trials. Expert Opin Biol Ther 8 Feb (2) (2008) 201-211
15. Grode L., Seiler P., Baumann S., Hess J., Brinkmann V., Nasser E.A., et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J Clin Invest 115 Sep (9) (2005) 2472-2479
16. Hoft D.F., Blazevic A., Abate G., Hanekom W.A., Kaplan G., Soler J.H., et al. A new recombinant bacille Calmette-Guerin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers. J Infect Dis 198 Nov (10) (2008) 1491-1501
17. Horwitz M.A., Harth G., Dillon B.J., and Maslesa-Galic S. Extraordinarily few organisms of a live recombinant BCG vaccine against tuberculosis induce maximal cell-mediated and protective immunity. Vaccine 24 Jan (4) (2006) 443-451
18. de Jonge M.I., Brosch R., Brodin P., Demangel C., and Cole S.T. Tuberculosis: from genome to vaccine. Expert Rev Vaccines 4 Aug (4) (2005) 541-551
19. Gutierrez M.C., Brisse S., Brosch R., Fabre M., Omais B., Marmiesse M., et al. Ancient origin and gene mosaicism of the progenitor of Mycobacterium tuberculosis. PLoS Pathog 1 Sep (1) (2005) e5
20. Leung A.S., Tran V., Wu Z., Yu X., Alexander D.C., Gao G.F., et al. Novel genome polymorphisms in BCG vaccine strains and impact on efficacy. BMC Genomics 9 (2008) 413
21. Liu J., Tran V., Leung A.S., Alexander D.C., and Zhu B. BCG vaccines: their mechanisms of attenuation and impact on safety and protective efficacy. Hum Vaccin 5 Feb (2) (2009)
22. Bonah C. The 'experimental stable' of the BCG vaccine: safety, efficacy, proof, and standards, 1921-1933. Stud Hist Philos Biol Biomed Sci 36 Dec (4) (2005) 696-721
23. Brimnes N. BCG vaccination and WHO's global strategy for tuberculosis control 1948-1983. Soc Sci Med 67 Sep (5) (2008) 863-873
24. BCG vaccine, freeze-dried-Vaccinum tuberculosis (BCG) cryodesiccatum. European Pharmacopoeia; 2009. Report No.: 01/2008:0163.
25. WHO. WHO requirements for dried BCG vaccine (1987), WHO, Geneva Report No.: WHO TRS No. 745
26. BCG for immunotherapy-BCG ad immunocurationem. European Pharmacopoeia; 2009. Report No.: 01/2009:1929.
27. Multiproduct manufacturing facilities. Genet Eng Biotechnol News 26 6 (2006) 1
28. Hamers M.N. Multiuse biopharmaceutical manufacturing. Biotechnology 11 May (5) (1993) 561-567 570
29. Chen Z.R., Cheng S.G., An Y.Q., and Cao X.H. Experimental research on utilization of bioluminescent technique to substitute the current viability count for BCG vaccine. Chin Med J (Engl) 102 Dec (12) (1989) 906-910
30. Ho M.M., Markey K., Rigsby P., Jensen S.E., Gairola S., Seki M., et al. Report of an international collaborative study to establish the suitability of using modified ATP assay for viable count of BCG vaccine. Vaccine 26 Aug (36) (2008) 4754-4757
31. Jensen S.E., Hubrechts P., Klein B.M., and Haslov K.R. Development and validation of an ATP method for rapid estimation of viable units in lyophilised BCG Danish 1331 vaccine. Biologicals 36 Sep (5) (2008) 308-314
32. Kairo S.K., Bedwell J., Tyler P.C., Carter A., and Corbel M.J. Development of a tetrazolium salt assay for rapid determination of viability of BCG vaccines. Vaccine 17 May (19) (1999) 2423-2428
33. Parra M., Yang A.L., Lim J., Kolibab K., Derrick S., Cadieux N., et al. Development of a murine mycobacterial growth inhibition assay for evaluating vaccines against Mycobacterium tuberculosis. Clin Vaccine Immunol 16 Jul (7) (2009) 1025-1032
34. Smith D., Wiegeshaus E., and Balasubramanian V. Animal models for experimental tuberculosis. Clin Infect Dis 31 Sep (Suppl. 3) (2000) S68-S70
35. Caccamo N., Guggino G., Meraviglia S., Gelsomino G., Di Carlo P., Titone L., et al. Analysis of Mycobacterium tuberculosis-specific CD8 T-Cells in patients with active tuberculosis and in individuals with latent infection. PLoS ONE 4 May (5) (2009) e5528
36. Cho S., Mehra V., Thoma-Uszynski S., Stenger S., Serbina N., Mazzaccaro R.J., et al. Antimicrobial activity of MHC class I-restricted CD8+ T cells in human tuberculosis. Proc Natl Acad Sci USA 97 Oct (22) (2000) 12210-12215
37. van Pinxteren L.A., Cassidy J.P., Smedegaard B.H., Agger E.M., and Andersen P. Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells. Eur J Immunol 30 Dec (12) (2000) 3689-3698
38. Smith S.M., Klein M.R., Malin A.S., Sillah J., Huygen K., Andersen P., et al. Human CD8(+) T cells specific for Mycobacterium tuberculosis secreted antigens in tuberculosis patients and healthy BCG-vaccinated controls in The Gambia. Infect Immun 68 Dec (12) (2000) 7144-7148
39. Flynn J.L., Goldstein M.M., Triebold K.J., Koller B., and Bloom B.R. Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. Proc Natl Acad Sci USA 89 Dec (24) (1992) 12013-12017
40. Horwitz M.A., and Harth G. A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis. Infect Immun 71 Apr (4) (2003) 1672-1679
41. Horwitz M.A. Recombinant BCG expressing Mycobacterium tuberculosis major extracellular proteins. Microbes Infect 7 May (5-6) (2005) 947-954
42. Horwitz M.A., Harth G., Dillon B.J., and Maslesa-Galic S. A novel live recombinant mycobacterial vaccine against bovine tuberculosis more potent than BCG. Vaccine 24 Mar (10) (2006) 1593-1600
43. Dose-Escalation Study on Safety and Immunogenicity of VPM1002 in Comparison With BCG in Healthy Male Volunteers. ClinicalTrials.gov; 2009. Report No.: NCT00749034.
44. Grode L., Kursar M., Fensterle J., Kaufmann S.H., and Hess J. Cell-mediated immunity induced by recombinant Mycobacterium bovis Bacille Calmette-Guerin strains against an intracellular bacterial pathogen: importance of antigen secretion or membrane-targeted antigen display as lipoprotein for vaccine efficacy. J Immunol 168 Feb (4) (2002) 1869-1876
45. Gonzalo-Asensio J., Mostowy S., Harders-Westerveen J., Huygen K., Hernandez-Pando R., Thole J., et al. PhoP: a missing piece in the intricate puzzle of Mycobacterium tuberculosis virulence. PLoS One 3 10 (2008) e3496
46. Ryndak M., Wang S., and Smith I. PhoP, a key player in Mycobacterium tuberculosis virulence. Trends Microbiol 16 Nov (11) (2008) 528-534
47. 2 based on phoP mutant. Vaccine 27 Apr (18) (2009) 2499-2505
48. Ferrer N.L., Gomez A.B., Soto C.Y., Neyrolles O., Gicquel B., Garcia-Del P.F., et al. Intracellular replication of attenuated Mycobacterium tuberculosis phoP mutant in the absence of host cell cytotoxicity. Microbes Infect 11 Jan (1) (2009) 115-122
49. Martin C., Williams A., Hernandez-Pando R., Cardona P.J., Gormley E., Bordat Y., et al. The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs. Vaccine 24 Apr (17) (2006) 3408-3419
50. Verreck F.A., Vervenne R.A., Kondova I., van Kralingen K.W., Remarque E.J., Braskamp G., et al. MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques. PLoS One 4 4 (2009) e5264
51. Larsen M.H., Biermann K., Chen B., Hsu T., Sambandamurthy V.K., Lackner A.A., et al. Efficacy and safety of live attenuated persistent and rapidly cleared Mycobacterium tuberculosis vaccine candidates in non-human primates. Vaccine 27 Jul (34) (2009) 4709-4717
52. Sambandamurthy V.K., Wang X., Chen B., Russell R.G., Derrick S., Collins F.M., et al. A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis. Nat Med 8 Oct (10) (2002) 1171-1174
53. Sambandamurthy V.K., and Jacobs Jr. W.R. Live attenuated mutants of Mycobacterium tuberculosis as candidate vaccines against tuberculosis. Microbes Infect 7 May (5-6) (2005) 955-961
54. Sambandamurthy V.K., Derrick S.C., Jalapathy K.V., Chen B., Russell R.G., Morris S.L., et al. Long-term protection against tuberculosis following vaccination with a severely attenuated double lysine and pantothenate auxotroph of Mycobacterium tuberculosis. Infect Immun 73 Feb (2) (2005) 1196-1203
55. Sambandamurthy V.K., Derrick S.C., Hsu T., Chen B., Larsen M.H., Jalapathy K.V., et al. Mycobacterium tuberculosis DeltaRD1 DeltapanCD: a safe and limited replicating mutant strain that protects immunocompetent and immunocompromised mice against experimental tuberculosis. Vaccine 24 Sep (37-39) (2006) 6309-6320
56. Hawkridge A., Hatherill M., Little F., Goetz M.A., Barker L., Mahomed H., et al. Efficacy of percutaneous versus intradermal BCG in the prevention of tuberculosis in South African infants: randomised trial. BMJ 337 (2008) a2052
57. Hesseling A.C., Caldwell J., Cotton M.F., Eley B.S., Jaspan H.B., Jennings K., et al. BCG vaccination in South African HIV-exposed infants-risks and benefits. S Afr Med J 99 Feb (2) (2009) 88-91
58. WHO. Guidelines on clinical evaluation of vaccines: regulatory expectations (2004), WHO, Geneva Report No.: TRS 924 Annex 1
59. Guideline for good clinical practice (1996), ICH Report No.: E6.(R1)
60. Hanekom W.A., Dockrell H.M., Ottenhoff T.H., Doherty T.M., Fletcher H., McShane H., et al. Immunological outcomes of new tuberculosis vaccine trials: WHO panel recommendations. PLoS Med 5 Jul (7) (2008) e145
61. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects (2008), World Medical Association Report No.: DoH/Oct2008
62. ICH harmonised tripartite guideline: clinical investigation of medicinal products in the pediatric population (2000), ICH Report No.: E11
63. International Ethical Guidelines for Biomedical Research Involving Human Subjects. http://www cioms ch/frame_guidelines_nov_2002 htm; 2002.
64. CFR21:50. Protection of Human Subjects. https://www accessdata fda gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch cfm?CFRPart=50; 2009CFR Title 21: Chapter 1: Part 50.
65. Pediatric Research Equity Act of 2003. ftp resource org/gpo gov/laws/108/publ155 108 pdf; 2003 Instrument Number:108-155. GLIN ID: 175685.
66. Directive 2001/18/EC of the European Parliament and of the Council of 12 March 2001 on the deliberate release into the environment of genetically modified organisms and repealing Council Directive 90/220/EEC - Commission Declaration. 2001. Report No.: Directive 2001/18/EC of the European Parliament.
67. Guideline on Environmental Risk Assessments for Medicinal Products Consisting of, or Containing, Genetically Modified Organisms (GMOs). http://www emea europa eu/pdfs/human/bwp/47319106en pdf; 2006.
68. Sparrow P.A. GM risk assessment. Methods Mol Biol 478 (2009) 315-330
69. Guidance document of the scientific panel on genetically modified organisms for the risk assessment of genetically modified microorganisms and their derived products intended for food and feed use (2009), European Food Safety Authority Report No.: EFSA-Q-2003-005B
70. Electronic submissions for regulatory approval (2004)
71. History and Future of ICH: A brief History of ICH. The Need to Harmonise. http://www ich org/cache/compo/276-254-1 html; 2009.
72. Council Directive 65/65/EEC of 26 January 1965 on the approximation of provisions laid down by Law, Regulation or Administrative Action relating to proprietary medicinal products. http://eur-lex europa eu/LexUriServ/LexUriServ do?uri=CELEX:31965L0065:EN:HTML; 1965.
73. Harman R.J. Development and control of medicines and medical devices (2004), Pharmaceutical Press
74. EU Guidelines to Good Manufacturing Practice Medicinal Products for Human and Veterinary Use Annex 19 Reference and Retention Samples. http://ec europa eu/enterprise/pharmaceuticals/eudralex/vol-4/pdfs-en/2005_12_14_annex19 pdf; 2005 December 14:1-5.
75. General Requirements for the Production and Control of Live Mammalian Bacterial and Viral Vaccines for Veterinary Use. http://www emea europa eu/pdfs/vet/vetguidelines/7blm1a pdf; 2009.
76. Guidance for Manufacturers on Clinical Investigations to be carried out in the UK. http://www mhra gov uk/Publications/Regulatoryguidance/Devices/GuidanceontheECMedicalDevices Directives/CON007504; 2006 October 1:1-44.
77. Guidance on Investigational Medicinal Products (IMPs) and other medicinal products used in Clinical Trials. http://ec europa eu/enterprise/pharmaceuticals/eudralex/vol-10/guidance-on-imp_nimp_04-20 07 pdf; 2008:1-7.
78. Opinions on medicines for use outside the European Union-Article 85. http://www emea europa eu/htms/human/non_eu_epar/background htm; 2009.
79. Brennan M.J. The US Food and Drug Administration provides a pathway for licensing vaccines for global diseases. PLoS Med 6 Jul (7) (2009) e1000095
80. Fast Track Drug Development Programs: Designation and Review Programs: SOPP 8414. http://www fda gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Proce duresSOPPs/ucm073515 htm; 2009.
81. Guidance for industry: fast track drug development programs-designation, development, and application review (2009), FDA Report No.: OMB Control No. 0910-0389
82. Guidance for Industry: Tropical Disease Priority Review Vouchers. http://www fda gov/OHRMS/DOCKETS/98fr/FDA-2008-D-0530-gdl pdf; 2009 Draft Guidance.
83. Brennan M.J., Fruth U., Milstien J., Tiernan R., de Andrade N.S., and Chocarro L. Development of new tuberculosis vaccines: a global perspective on regulatory issues. PLoS Med 4 Aug (8) (2007) e252
84. African Vaccine Regulatory Forum (AVAREF). http://www who int/immunization_standards/vaccine_regulation/africa_network/en/index html; 2009.